Effect of piribedil on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia.
In women with physiological puerperal hyperprolactinaemia, acute administration of Piribedil (100 mg po), a drug which stimulates dopamine receptor sites, was as effective as that of 2-Br-alpha-ergocryptine (CB 154, 5 mg po) in suppressing the elevated baseline plasma prolactin (PRL) levels. In two hyperprolactinaemic women with radiological evidence of an intrasellar pituitary tumour, Piribedil (100 mg po), in contrast to CB 154 (5 mg po), failed to modify plasma PRL levels, whereas in 3 other hyperprolactinaemic women with no radiological evidence of pituitary tumour, its effect was not clear-cut, even though it could not be differentiated from that of CB 154. These results indicate that Piribedil is an effective suppressor of plasma PRL levels in the human and suggest that its action is more evident in puerperal than in pathological hyperprolactinaemia.
D000568:Amenorrhea / Q000097:blood; D001971:Bromocriptine / Q000494:pharmacology; D003864:Depression, Chemical; D005260:Female; D005687:Galactorrhea / Q000097:blood*; D006801:Humans; D007775:Lactation Disorders / Q000097:blood*; D010879:Piperazines / Q000494:pharmacology*; D010891:Piribedil / Q000494:pharmacology*; D049590:Postpartum Period; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*
D010879:Piperazines; D001971:Bromocriptine; D011388:Prolactin; D010891:Piribedil